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a b s t r a c t
Ectromelia virus (ECTV) is the causative agent of mousepox, a disease of laboratory mouse colonies and
an excellent model for human smallpox. We report the genome sequence of two isolates from outbreaks
in laboratory mouse colonies in the USA in 1995 and 1999: ECTV-Naval and ECTV-Cornell, respectively.
The genome of ECTV-Naval and ECTV-Cornell was sequenced by the 454-Roche technology. The ECTV-
Naval genome was also sequenced by the Sanger and Illumina technologies in order to evaluate these
technologies for poxvirus genome sequencing. Genomic comparisons revealed that ECTV-Naval and
ECTV-Cornell correspond to the same virus isolated from independent outbreaks. Both ECTV-Naval and
ECTV-Cornell are extremely virulent in susceptible BALB/c mice, similar to ECTV-Moscow. This is
consistent with the ECTV-Naval genome sharing 98.2% DNA sequence identity with that of ECTV-
Moscow, and indicates that the genetic differences with ECTV-Moscow do not affect the virulence of
ECTV-Naval in the mousepox model of footpad infection.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
Mousepox is an acute exanthematous disease of mice caused by
the orthopoxvirus (OPV) ectromelia virus (ECTV) that in the past
century affected laboratory mouse colonies worldwide (Esteban
and Buller, 2005; Fenner, 1981; Marchal, 1930). ECTV, like variola
virus (VARV), the causative agent of smallpox, has a narrow host
range and causes a severe disease with skin lesions in the later
stages of the infection and a high mortality rate (Esteban and
Buller, 2005). Mousepox was ﬁrst described in 1930 in Hampstead
(United Kingdom) as an infectious disease of mouse associated
with high mortality and amputations in mice recovered
from infection (Marchal, 1930). Following the identiﬁcation of
ECTV-Hampstead, ECTV has been isolated in temporally and
geographically different laboratory mousepox outbreaks. ECTV-
Moscow is a highly virulent strain isolated in Moscow in 1947 and
extensively used in pathogenesis studies, and ECTV-Ishibashi,
isolated in Japan in 1966, was used in the initial ECTV studies
(Allen et al., 1981; Andrewes and Elford, 1947; Ichihashi and
Matsumoto, 1966). Several important mousepox outbreaks
occurred in the USA between the seventies and the eighties. As a
consequence, tens of thousands of laboratory mice were sacriﬁced
and millions of dollars were lost in biomedical research (Lipman et
al., 1999). ECTV-NIH79 was a virulent strain isolated in 1979 at the
National Institutes of Health (NIH) in Bethesda, Maryland (USA)
(Allen et al., 1981). In the same period, various outbreaks were
reported in biomedical research institutions in Saint Louis, Chi-
cago, Minneapolis and Salt Lake City (Dixon, 1981; La Regina and
Doyle, 1981; Wallace, 1981). Because the clinical signs of mouse-
pox are not evident in resistant mouse strains, ECTV infections
could have been present in colonies for long periods before their
identiﬁcation in animal house facilities in USA. The destruction of
entire mouse colonies was not always satisfactory to control
mousepox spread (Wallace, 1981). In order to ﬁght this continuous
threat, working with live ECTV was prohibited in the USA (Fenner
et al., 1989). In 1995, the virulent strain ECTV-Naval caused an
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outbreak in the laboratory mouse colony of the US Naval Medical
Research Institute in Bethesda, Maryland (USA) (Dick et al., 1996).
The outbreak caused devastating effects and ended with the
sacriﬁce of thousands of mice, affecting more severely the BALB/
c mice (Dick et al., 1996). The last outbreak of mousepox was
reported in 1999 at the Weill Medical College of Cornell University
in New York (USA), and was successfully contained and eradicated
from the animal house facility (Lipman et al., 1999, 2000). Contrary
to initial speculations about the existence of a natural reservoir for
this virus within the USA, it was found that the Cornell University
outbreak originated from an injection of mice with a contaminated
commercial mouse serum imported in 1995 from China, and
the same origin was speculated for the outbreak in Bethesda that
occurred four years earlier (Lipman et al., 1999, 2000). ECTV
outbreaks have no longer been reported (Huggins et al., 2009),
probably due to improved housing conditions of laboratory mouse
colonies and routine testing of the health status of mouse colonies.
Nearly a century after the ﬁrst ECTV description, it is intriguing
that this virus has never been isolated from a mouse or rodent in
nature, and its natural reservoir remains unknown (Fenner et al.,
1989). The only exception was a report describing a putative ECTV
infection in ﬁeld mice in Germany in 1962. This disease could be
transmitted by footpad inoculation to laboratory white mice and
produced typical symptoms of ECTV infection, including skin
lesions, foot inﬂammation and amputation (Groppel, 1962). How-
ever, the virus was not isolated and the presence of ECTV was not
conﬁrmed by molecular techniques.
The growing fear of the possible use of VARV as a bioterrorist
weapon causing an epidemic in the human population that is no
longer vaccinated against the disease prompted the need for the
development of safer smallpox vaccines (Smith and McFadden, 2002).
Moreover, OPV zoonoses have increased in recent years; monkeypox
virus (MPXV) may occupy the niche vacated by VARV in Africa and
cowpox virus (CPXV) is transmitted to humans by domestic animals
and occasionally wild rodents in Europe (Favier et al., 2011; Giulio and
Eckburg, 2004; Wolfs et al., 2002). The major limitation for the
improvement of the current repertoire of poxvirus vaccines is the lack
of accessible human OPV infections for clinical efﬁcacy trials. The
genetic similarity of ECTV to VARV, CPXV and MPXV, together with
the convenience of a laboratory mouse model, underscores the utility
of mousepox as a model for the study of OPV infections (Buller, 2004).
The recent development of next generation sequencing tech-
nologies has had a pronounced impact on virology providing a
fundamental tool for sequencing large viral genomes (Afonso et al.,
2012; Lin et al., 2013; Mavian et al., 2014, 2012a, 2012b; Qin et al.,
2013) for metagenomic studies of viral communities (Lopez-Bueno
et al., 2009; Reyes et al., 2010) and also for the identiﬁcation of
new viruses and pathogens (Radford et al., 2012). In spite of the
relevance of the mousepox model, only two ECTV genomes have
been sequenced: ECTV-Moscow and Erythromelalgia-related pox-
virus (ERPV), an ECTV strain isolated in China from throat speci-
men of individuals affected by erythromelalgia, a vascular disease
of extremities and characterized by hyperthermia and vasodilata-
tion (Chen et al., 2003; Mendez-Rios et al., 2012; Zheng et al., 1992,
1988). Here we report the sequence of the ECTV-Naval and ECTV-
Cornell genomes determined by three different sequencing tech-
nologies (Sanger, 454-Roche and Illumina) and deﬁne the viru-
lence of these isolates in susceptible mice.
Results
Plaque puriﬁcation of ECTV-Naval.Cam
The plaque-puriﬁed ECTV-Naval.Cam stock was obtained after
three rounds of plaque puriﬁcation of a single plaque derived from
the spleen of a BALB/c mouse infected with the original stock of
the Naval Medical Research Institute outbreak (Bethesda, Mary-
land, USA) (Dick et al., 1996). The virulence in susceptible BALB/c
mice of ECTV-Naval.Cam is similar to that of the original uncloned
stock, indicating that the plaque-puriﬁed virus has not been
attenuated and is representative of the parental virus isolate (data
not shown). ECTV-Naval.Cam is referred in the text as ECTV-Naval.
Sequencing of the ECTV-Naval genome
The genome of ECTV-Naval has been sequenced by three
different sequencing technologies: Sanger, 454-Roche and Illu-
mina. Sequences obtained by Sanger (5810 reads with an average
length of 536 bp) were assembled into ﬁve contigs accounting for
202 Kbp. Further 42 reads were obtained to close gaps and to raise
the quality of low coverage regions. Finally, a contiguous linear
sequence of 207,620 bp with 13 coverage was attained (Table 1).
The leftmost nt was an arbitrarily designated base one. The ITR of
the genome contains the OPV speciﬁc structures: the hairpin loop,
the concatemer resolution motif, two sets of direct repeats (DRI
and DRII) and the non-repetitive I (NRI) and NRII sequences
ﬂanking DRI. The DRI of the ECTV-Naval genome, as for ECTV-
Moscow, is formed by a unique sequence of 68 bp, in comparison
with the 69 bp sequence repeated 2.3 of ERPV (Chen et al.,
2003; Mendez-Rios et al., 2012). DRII contains an 85 bp sequence
repeated 19.4 , instead of 10.4 found in the ECTV-Moscow and
ERPV genomes (data not shown) (Chen et al., 2003; Mendez-Rios
et al., 2012). A third set of direct repeats, located in the central
region of the genome (DRIII), contained a 24 bp (“TCTATATCCTG-
TACTATACCATTA”) sequence repeated 25 . Although the hairpin
loop structure was not experimentally isolated and sequenced, the
comparison by clustalw2 alignment with the sequence of the
termini of the ECTV-Moscow and ERPV genomes suggested that
the genome was represented completely in the sequence, includ-
ing the hairpin loop structures.
The 454-Roche sequencing output consisted of 92,155 reads
with an average length of 360 bp (Table 1). The 454-Roche reads
were assembled into two contigs of approximately 35 Kbp and
163 Kbp, separated by the DRIII region. Sanger sequencing of a PCR
product including the DRIII region also failed to determine the
exact number of repeats. We estimated by gel electrophoresis of
the PCR product the presence of 17 repeats of 24 bp in the DRIII
region (Fig. 1). The genome sequence obtained by 454-Roche has a
size of 204,205 bp, including a DRII region of 85 bp sequence
repeated only 2.3 (Table 1). The coverage of the genome was
83 , almost seven times higher than the coverage obtained by
Sanger. This 454-Roche genome showed eight differences when
compare to the genome obtained by Sanger, mostly due to A/T
homopolymeric regions.
Table 1
DNA sequencing of the ECTV-Naval and the ECTV-Cornell genomes.
ECTV-Naval ECTV-Cornell
Sanger 454-Roche Illumina 454-Roche
Total reads 5810 92,155 5,497,834 67,965
Mapped reads (%)a nd 45,195 4,835,589 58,558
(49.0%) (87.9%) (86.1%)
Average reads size (bp) 536 360 76 384
Genome coverage (x) 13 83 1770 115
Genome size (bp) 207,620 204,099 207,620 204,499
Differences with Sanger
genome b
– 8 0 nd
nd, not determined.
a Number of reads mapped to the reference viral genome .
b Number of nucleotide differences as compared to the Sanger genome.
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The genome sequence determined by Illumina was 207,620 bp
long with a coverage of 1770 , which was 21 times and 147 times
higher than those obtained by 454-Roche and Sanger sequencing,
respectively (Table 1). The genome determined by Illumina was
identical in sequence to that obtained by Sanger.
In conclusion, the ECTV-Naval genome reported here corre-
sponds to the genome sequence obtained by Sanger and Illumina,
but considering the 17 repeated sequences in the DRIII region
estimated by gel electrophoresis (Fig. 1). With a total size of
207,428 bp, this genome contains an ITR of 7377 bp and shows
an A/T typical OPV composition of 66.87%.
Variability in the number of repeats in the DRIII region among ECTV
isolates
Since the DRIII region appeared to be highly variable, we
compared the length variation of this region in a collection of
ECTV isolates available in our laboratory (Smith and Alcami,
2000): (i) ECTV-Moscow, plaque-puriﬁed from the virus isolated
in an outbreak in Moscow in 1947 (Andrewes and Elford, 1947);
(ii) ECTV-Hampstead, the ﬁrst ECTV isolated in 1930 from London
(Marchal, 1930); (iii) ECTV Hampstead-Egg and ECTV-Mill Hill,
derived from the ECTV Hampstead isolate by serial passage in eggs
(Smith and Alcami, 2000); (iv) ECTV-Ishibashi, a plaque puriﬁed
virus derived from an outbreak in Japan in 1966 (Ichihashi and
Matsumoto, 1966); (v) two isolates ECTV-MP1 (München, 1976)
and ECTV-MP4 (Nürnberg, 1976) from German outbreaks (Mahnel,
1983; Osterrieder et al., 1994); (vi) ECTV-MP5 from an outbreak in
Wien (Austria) in 1994 (Osterrieder et al., 1994); and (vii) ECTV-
Cornell isolated in the most recent outbreak in the USA (Lipman et
al., 2000). A high variability in the number of repeats was detected
among all the ECTV strains (Fig. 1) ranging from 15 repeats for
ECTV Hampstead-Egg to 45 repeats estimated for ECTV-Cornell.
Interestingly, different number of repeats were determined by PCR
ampliﬁcation followed by agarose gel analysis and by Sanger
sequencing for ECTV-Naval (17 vs. 25 repeats, respectively) and
for ECTV-Moscow (29 vs. 30 repeats, respectively) (Chen et al.,
2003). An alternative method to estimate the number of repeats in
DRIII was to consider the number of Illumina sequencing reads
aligned to this region compared to the number of sequencing
reads in ﬂanking non-repetitive regions of the genome. We
estimated in this way the presence of 15 repeats in the DRIII
region of the ECTV Naval genome, which was very close to the 17
repeats estimated by PCR ampliﬁcation and agarose gel.
Annotation of the ECTV-Naval genome
Non-overlapping ORFs, with a minimum of 120 nt, encoding for
proteins with similarity to a poxvirus ortholog of known function
or conserved domains, were annotated as genes. Genes that were
fragmented due to the presence of mutations, deletions or inser-
tions that interrupted translation of the protein were designated
as pseudogenes and named with a ‘P’. Genes as well as pseudo-
genes were given a number according to their position in the
genome (Fig. 2, Table S1). A total of 206 putative genes were
annotated in the ECTV-Naval genome: 174 genes and 32 pseudo-
genes. All genes shared more than 90% identity with the orthologs
from the vaccinia virus strain Copenhagen (VACV-Cop), CPXV-BR
or VARV-BSH reference genomes (Table S1). The genome of ECTV-
Naval showed the typical poxviral genomic organization with
essential genes in the central region of the genome and genes
involved in virus-host interaction in the terminal regions of the
genome.
The conserved region of the genome of ECTV-Naval includes
essential genes that are involved in DNA replication and RNA
transcription (47 genes) or morphogenesis (53 genes) (Fig. 2, Table
S1). It has been reported that 90 genes in the central region of
VACV-Cop, from F9L to A34R, deﬁne the minimal gene content
conserved in all the chordopoxvirus genera (Lefkowitz et al.,
2006). These genes in the ECTV-Naval genome, from EVN049 to
EVN156, are conserved in VACV-Cop and VARV-BSH, with a few
exceptions. For example, EVN064 and EVN136 are absent in VARV-
BSH; EVN147, that encodes for the A-type inclusion body protein
(ATIp), is present in CPXV-BR but fragmented in VACV-Cop and
VARV-BSH; and EVN148P, a pseudogene of the P4c gene, is
fragmented in CPXV-BR whereas it is a full-length gene in VACV-
Cop and VARV-BSH (Table S1).
Genes that modulate the host immune system or determine the
host range (42 genes) are located in the variable terminal regions
of the genome (Fig. 2, Table S1). These regions include genes
encoding the viral growth factor, semaphorin homolog, ankyrin-
like and kelch-like proteins involved in determining host range,
inhibition of the ubiquitin proteasome system and apoptosis (Seet
et al., 2003; Shchelkunov, 2012), and several secreted proteins
which modulate inﬂammatory responses by sequestering cyto-
kines such as receptor/binding proteins for chemokines, interleu-
kin (IL)-1β, interferon (IFN)-α/β, IFN-γ and tumor necrosis factor
(TNF) (Alcami et al., 1998; Graham et al., 1997; Loparev et al., 1998;
Sakala et al., 2007; Smith et al., 1997; Smith and Alcami, 2000,
2002; Xiang and Moss, 1999; Xu et al., 2008) (Table S1). A total of
33 genes have no function ascribed (Fig. 2, Table S1).
Seventeen pseudogenes are present in the right terminal region
of the genome, 14 in the left terminal region and only one
(EVN148P) in the central region of the genome (Fig. 2, Table S1).
Three genes and three pseudogenes are found in the ITR, which
are consequently diploid. The duplicated genes encode for a
chemokine binding protein (35 kDa), a TNF receptor/chemokine
binding protein (Cytokine response modiﬁer D, CrmD) and an
ankyrin-like protein that blocks NF-kB activation (Alcami et al.,
1998; Graham et al., 1997; Loparev et al., 1998; Rubio et al., 2013).
Interestingly, whereas CPXV encodes four TNF receptors (CrmB,
CrmC, CrmD and CrmE), ECTV conserves only one functional
protein, CrmD encoded by the EVN006 gene, and the genes
encoding CrmB, CrmE and CrmC are mutated, corresponding to
pseudogenes EVN002P, EVN005P and EVN175P, respectively (Alejo
et al., 2011) (Fig. 2, Table S1). The pseudogene EVN007P has not
been fully duplicated laying in the intersection between the ITRs
and the unique sequence.
Comparison with the ECTV-Moscow genome annotation
showed several differences (Tables S1 and S2) (Chen et al.,
2003). The ECTV-Naval EVN071 gene is a new ORF that was
Fig. 1. Variability of the DRIII region among ECTV strains. (A) The locations of the
DRI, DRII and DRIII regions in the schematic representation of the ECTV genome are
shown. The DRIII region was PCR-ampliﬁed from genomic DNA and analyzed by 2%
agarose gel electrophoresis. Molecular size markers (Ladder) are shown. (B) The
estimated number of 24 bp repeats for each ECTV strain is shown. H, ECTV-
Hampstead; HE, ECTV-Hampstead Egg; I, ECTV-Ishibashi; MH, ECTV-Mill Hill;
M1, ECTV-MP1; M4, ECTV-MP4; M5, ECTV-MP5; C, ECTV-Cornell; N, ECTV-Naval;
M, ECTV-Moscow.
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not annotated in the ECTV-Moscow genome. The ortholog of
this novel gene in VACV-Cop, O3L, has been recently described
to encode a small protein of 35 amino acids implicated in the
formation of the entry/fusion complex (Satheshkumar and Moss,
2009). The EVN010P pseudogene is formed by two fragments
of the same gene that in ECTV-Moscow has been annotated as
separate and independent gene (Chen et al., 2003). These frag-
ments show sequence similarity to the C-type lectin encoded by
CPXV-Germany 91-3 (ABD97357) (data not shown). The truncated
version of this protein in CPXV-BR, CPXV012, is responsible
for down-regulation of major histocompatibility complex class
I molecules (Alzhanova et al., 2009; Byun et al., 2007). Despite
sharing a 67% of amino acid sequence similarity with the ﬁrst 46
amino acids of the CPXV012 protein, neither the truncated protein
from ECTV-Moscow, nor the smaller protein from ECTV-Naval
seem to be functional (Alzhanova et al., 2009; Byun et al., 2007).
The ortholog of EVM144, encoding a superoxide dismutase in
VACV-Cop A45R (Almazan et al., 2001; Cao et al., 2002) has lost
18 amino acids from its C-terminus in ECTV-Naval, and therefore
has been annotated as pseudogene EVN167P. This truncation is due
to the deletion of an adenine in a homopolymeric region that has
been conﬁrmed by the Sanger and Illumina sequencing. The ECTV-
Naval gene EVN019 codes for an IL-18 binding protein of 126 amino
acids, whereas its ECTV-Moscow ortholog EVM013 is 12 amino
acids longer. The IL-18 binding protein encoded by both ECTV-
Naval and ECTV-Moscow have been shown to be active (Esteban
and Buller, 2004; Smith and Alcami, 2000). The ECTV-Naval
EVN038 gene, that codes for a DNAse with a size of 424 amino
acids, is truncated (372 amino acids) in the ECTV-Moscow genome
and it was annotated as a pseudogene (Region N) (Chen et al.,
2003). Differences between ECTV-Naval and ECTV-Moscow also
include some amino acid mutations in a number of proteins
(Table S2). In summary, the ECTV-Naval genome has 98.2%
sequence identity with the ECTV-Moscow genome, and the pre-
dicted functional differences are limited to a shorter IL-18 binding
protein (EVN019), a truncated superoxide dismutase (EVN167P)
and a longer DNAse (EVN038) in ECTV-Naval, in addition to amino
acid mutations in several proteins (Tables S1 and S2).
Unlike the recent ERPV annotation, but similar to the ECTV-
Moscow annotation, we have annotated EVN026P and EVN174P as
pseudogenes. EVN026P encodes only 106 amino acids of the 204
amino acids of its VACV-Cop ortholog C5L, having lost the kelch/
BTB domain. This pseudogene is identical to that of ECTV-Moscow,
annotated as ‘Region I’ and to the annotated gene ERPV017 of ERPV.
EVN174P is an ortholog of VACV-Cop A52R, an inhibitor of
intracellular signaling mediated by IL-1, IL-18 and Toll-like recep-
tors, and codes for a 33% smaller protein (Baxby, 1982; Bowie et al.,
2000; Harte et al., 2003) (Table S1).
The ECTV-Cornell genome: sequencing, annotation and comparison
with the ECTV-Naval genome
The ECTV-Cornell isolate, obtained from the Weill Medical
College of Cornell University outbreak (Lipman et al., 2000), was
not plaque-puriﬁed. The ECTV-Cornell genome was sequenced by
the 454-Roche technology and, like the ECTV-Naval genome, was
assembled into two contigs separated by the DRIII region consist-
ing of 45 repeats of a 24 bp sequence, as estimated by gel
electrophoresis (Fig. 1).
The ECTV-Cornell genome has a size of 204,499 bp with a
coverage of 115 , including two copies of the 85 bp sequence of
the DRII region (Table 1). The initial annotation of the ECTV-
Cornell revealed that three genes (EVC019, EVC077 and EVC133)
were interrupted due to incorrect estimation of the length of A/T
homopolymers. PCR ampliﬁcation of homopolymeric regions was
carried out to determine the exact number of A/Ts and conﬁrmed
Fig. 2. Schematic organization of the ECTV-Naval genome. Predicted putative genes are represented as arrows indicating the approximate size and direction of transcription.
The color of the arrows indicate the predicted function: red, immunomodulatory and host range; yellow, metabolism; orange, structural proteins and morphogenesis; brown,
unknown function. Pseudogenes are indicated as dark gray rectangles. ITRs are marked as a green line.
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that full-length genes are also present in ECTV-Cornell (data not
shown).
The ECTV-Naval and ECTV-Cornell genomes are almost iden-
tical to each other with a 99.9% identity, differing only in four
positions of the genome (Table 2); the number of 24 nt repeats
determining a different number of “DIDNGIVQ” in the EVN041/
EVC041 genes, two single nt synonymous changes affecting genes
EVN160/EVC160 and EVN165/EVC165, and a different size in the
homopolymer of the position 155,375 of the ECTV-Naval genome
affecting the EVN162P/EVC162P pseudogenes. The ECTV-Naval and
ECTV-Cornell genomes are very similar to the genome of ERPV,
differing only in 12 positions, nine of which are affecting putative
genes (Table 2).
Virulence of ECTV-Naval and ECTV-Cornell
The virulence of ECTV-Naval and ECTV-Cornell in susceptible
BALB/c mice was compared to that of ECTV-Moscow. Severe
mousepox disease and death was caused by ECTV-Moscow,
ECTV-Naval and ECTV-Cornell at 1 pfu per mouse indicating an
LD50o1 pfu (Fig. 3). The time of death (12–19 dpi) and weight loss
(average of 7.2% at 9 dpi) were indistinguishable in mice infected
with these viruses. All mice suffered severe signs of illness
(hunched posture, conjunctivitis and reduced mobility) but lim-
ited foot swelling was observed. With higher doses of 10 and
102 pfu per mouse, mortality and disease progression were similar
but foot swelling started 1–2 days earlier in mice infected with
ECTV-Moscow. Footpad infection of susceptible DBA/2 mice with
0.1, 1, 10 and 102 pfu of ECTV-Naval or ECTV-Moscow showed a
LD50o1 pfu for both viruses (data not shown).
Discussion
ECTV is the causal agent of mousepox, an OPV infection of mice
that affected animal facilities in Europe, Asia and USA during
the past century. ECTV-Naval and ECTV-Cornell are isolates that
caused two separate outbreaks in laboratory mouse colonies in
USA. We report the genomic sequence of ECTV-Naval, sequenced
with three different technologies (Sanger, 454-Roche and Illu-
mina), and ECTV-Cornell, sequenced with 454-Roche.
The complete genome sequence of ECTV-Naval obtained with
the Sanger method or Illumina sequencing were identical, whereas
the 454-Roche technology failed to determine the exact number of
nt in homopolymers of more than six consecutive A/T bases.
Several of these errors in homopolymers caused the introduction
of early stop codons in some ORFs. The need to correct these errors
by further steps of PCR ampliﬁcations and Sanger sequencing
limits the use of the 454-Roche technology for de novo sequencing
or re-sequencing of OPV genomes or any other genome with a
high A/T content. We concluded that Illumina appears to be a more
solid technology, in terms of quality and cost-beneﬁt when
sequencing poxvirus genomes with a close reference genome
available. It has been proposed that the 454-Roche technology
might be a better choice for de novo assembly of poxviral genomes
without a related reference genome, due to the longer sequences
obtained. However, the recent increase in read length attained
with the Miseq platform (2300 bp), together with its higher
coverage, will make this technology most suitable for de novo
assembly of large viral genomes.
Nevertheless, we found that Sanger, 454-Roche and Illumina
present a common limitation. These three technologies are not
able to determine the exact number of repeated sequences that
cover a portion of the genome larger than the average size of the
output reads. To solve this problem we performed a gel electro-
phoresis estimation of the length of the PCR products and it
revealed a high variability in the number of repeats among all the
ECTV strains, whereas only a few copies are present in VACV and
CPXV (Yu et al., 2011). It is unlikely that these repeats have
originated artiﬁcially during the Phi29 polymerase ampliﬁcation
step in library production because they were found in the
genomes of ECTV sequenced by Sanger: ECTV-Naval (this publica-
tion) and ECTV-Moscow (Chen et al., 2003). This variability is
likely due to a DNA polymerase slippage event occurring during
viral DNA replication, normally described for short tandem repeats
of three bases but also possible for longer sequences (Streisinger et
al., 1966). This viral DNA polymerase slippage could explain the
high variability in the number of repeats found in different ECTV
isolates or virus stocks. Indeed, the ECTV-Naval and ECTV-Moscow
DNA template used for the Sanger sequencing of the genomes (25
and 30 repeats, respectively) and those used for the PCR gel
estimation (17 and 29 repeats, respectively) derived from distinct
viral ampliﬁcations. A mixture of genomes with different number
of repeats was even observed within the same virus stock in our
gel analysis of PCR products. The repeats are located within the
EVN041 gene, the ortholog of VACV-Cop F1L, and encode numerous
reiterations of eight amino acids (“DIDNGIVQ”). Despite this
variation in protein length the crystal structure of VACV-Cop F1
indicates that the structural determinants essential for the inhibi-
tion of caspase 9 are preserved, and that even if 45 repeats of
“DIDNGIVQ” are present, as for ECTV-Cornell, the protein may be
active (Yu et al., 2011).
In order to ensure that genes were correctly annotated, we
have taken into account recently published data describing novel
gene functions, such as the VACV-Cop O3 protein, a component of
the entry/fusion complex (Satheshkumar and Moss, 2009), or
recently deﬁned structural domains, such as the VACV-Cop F1
protein (Yu et al., 2011). ORFs with mutations that cause the loss of
Table 2
Differences among the genomes of ECTV-Naval, ECTV-Cornell and ERPV.
Position in ECTV-Naval ORF ECTV-Naval ECTV-Cornell ERPV Amino acid differences
36,910 EVN041 1724 pb 4524 pb 724 pb Variable number of “DIDNGIVQ”
55,612–55,613 EVN062 – – AT 10 aa N-terminal deletion
130,142 EVN081 T T C V66A
127,552 EVN131 A A G R236G
125,616 EVN131 T T C V881A
152,911 EVN160 T C C –
155,375 EVN162P 11C 9C 7C –
158,361 EVN165 G T G –
159,104 EVN166P 5A 5A 6A –
159,383 EVN167 T T C S67P
167,577 EVN176 A A G N358D
168,661 EVN177 T T G Y139D
189,833 EVN196 A A G M241V
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an initiator methionine or the introduction of stop codons and
frameshifts leading to the fragmentation of genes otherwise active
in other poxviruses were annotated as pseudogenes. These frag-
mented genes are often found in viral genomes, probably reﬂect-
ing that the mutations were introduced recently during evolution.
This common phenomenon in OPV genomes leads to the identi-
ﬁcation of small ORFs that correspond to fragments of the active
gene or new ORFs derived from translation of an alternative
reading frame, even in the reverse orientation to the original
gene. The latter is very often misleading because it may be
interpreted as the presence of a new gene in a particular virus
whereas the reality is that a genuine gene located in that position
is fragmented. Pseudogenes highlight the absence of an active
gene, information that may be relevant to evaluate the contribu-
tion of such gene to viral pathogenesis. Pseudogenes were only
annotated when there was clear evidence for the existence of the
active ortholog gene, either from comparative analysis of other
poxvirus genomes and/or from functional data available in the
published literature. When this was not clear or the genes were
truncated and could still retain activity, they were annotated as
genes. We have named pseudogenes with the corresponding order
gene number and added the letter ‘P’ to distinguish them from
genes and to simplify a possible change of pseudogene to gene, if
its functionality is demonstrated in the future. We believe that this
annotation will provide a better interpretation of the coding
capacity of poxvirus genomes.
The ECTV-Naval and ECTV-Cornell genomes are almost iden-
tical, differing in four silent mutations and in the number of the
24 nt direct repeats. The number of repeats is unlikely to con-
tribute to virulence since they can vary even between stocks of the
same ECTV. Moreover, the in vivo experiments showed an
LD50o1 pfu per mouse for both ECTV-Naval and ECTV-Cornell in
BALB/c mice. In light of these results, it is conceivable that ECTV-
Naval and ECTV-Cornell are the same virus. Further evidence
Fig. 3. Virulence of the ECTV-Moscow, ECTV-Naval and ECTV-Cornell isolates in BALB/c mice. Groups of ﬁve female 5–6 week old mice were subcutaneously infected in the
footpad with different doses of ECTV-Moscow (A), ECTV-Naval (B) or ECTV-Cornell (C) (1, 10 and 102 pfu per mouse). Mortality (%), weight (%), swelling of the foot (mm) and
signs of illness are represented.
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supporting this hypothesis is that the outbreak at Cornell Uni-
versity was caused by the injection of mice with a contaminated
commercial serum imported in 1995 from China, the same year
the outbreak occurred in the Naval Medical Research Institute,
associated also with the use of a contaminated mouse serum (Dick
et al., 1996; Lipman et al., 1999). This suggests that both outbreaks
were caused by the same ECTV present in the mouse serum batch
imported to the USA at that time. ECTV-Naval shares a 99.8%
nucleotide identity with ERPV (Mendez-Rios et al., 2012). The
similarity of ERPV to ECTV-Naval, together with the origin of the
mouse imported serum, indicate that these viruses originated in
China and support the presence of an ECTV reservoir in that
country. Several records describing ERPV mention the existence of
a previous Chinese ECTV from the early 1960s and at least six
isolates of ERPV have been described (Zheng et al., 1992, 1988).
Materials and methods
Cells and viruses
Monkey kidney BS-C-1 cells (ATCC: CCL-26) were grown in
Dulbecco's modiﬁed Eagle's medium supplemented with 10%
heat-inactivated fetal bovine serum (Gibco BRL). Plaque-puriﬁed
ECTV-Moscow-3-P2 (ECTV-Moscow) (Chen et al., 2003), derived
from the original stock of F. Fenner (Andrewes and Elford, 1947),
and ECTV-Naval, the original stock of the Naval Medical Research
Institute outbreak (Bethesda, Maryland, USA) (Dick et al., 1996),
were provided by R. M. L. Buller (School of Medicine, Saint Louis
University). Plaque-puriﬁed ECTV-Naval.Cam was derived from
ECTV-Naval as follows. A BALB/c mouse was infected with ECTV-
Naval and 7 days after infection the spleen was homogenized and
several dilutions plated on BS-C-1 cell monolayers. A virus plaque
was clonally isolated through three rounds of plaque puriﬁcation
on BS-C-1 cells obtaining ECTV-Naval.Cam. ECTV-Naval.Cam is
referred in the text as ECTV-Naval. ECTV-Cornell isolated from
the Weill Medical College of Cornell University outbreak (Lipman
et al., 2000) was provided by H. Meyer (Institute of Microbiology,
Federal Armed Forces Medical Academy, Munich, Germany) and N.
Lipmann (Weill Medical College of Cornell University, New York, N.
Y.). The source of the ECTV isolates Hampstead, Hamstead-Egg,
Mill-Hill, Ishibashi, MP1, MP4 and MP5 are described elsewhere
(Smith and Alcami, 2000).
Viral stocks for animal experiments and isolation of DNA were
obtained from semi-puriﬁed viral particles. Brieﬂy, BS-C-1 cells
were infected at a multiplicity of infection of 0.01 plaque forming
units (pfu) per cell and homogenized by serial syringe passages.
Nuclei and cell debris were discarded by centrifugation at 900g for
10 min at 4 1C, and viral particles were isolated by ultracentrifuga-
tion at 20,000g for 1 h at 4 1C through a 36% sucrose cushion and
resuspended in 10 mM Tris pH 9.
Isolation of viral DNA
Free DNA from semi-puriﬁed viral stocks was digested with
DNAse I (500 Units/ml) (Roche), Nuclease S7 Micrococcal (500
Units/ml) (Roche) and RNAse A (20 μg/ml) (Roche). After protei-
nase K (200 μg/ml) (Invitrogen) and 0.5% sodium dodecyl sulfate
treatment, viral DNA was extracted with phenol/chloroform and
precipitated with 0.1 volume of 3 M sodium acetate pH 5.3 and
2.5 volumes of ethanol in the presence of 10 μg/ml of oyster
glycogen (Roche) as carrier. In the case of 454-Roche and Illumina
sequencing, viral DNA was subsequently puriﬁed by gel electro-
phoresis with 1% low melting agarose (MicroSieve Clone LM
agarose, Flowgen Bioscience) and extracted with the QIAquick
Gel Extraction Kit (Qiagen), and puriﬁed viral DNA was ampliﬁed
by multiple displacement ampliﬁcation using Phi29 DNA Polymer-
ase as described by the manufacturer (Illustra GenomiPhi V2 DNA
Ampliﬁcation Kit; GE Healthcare). Phi29-ampliﬁed viral DNA
was precipitated with ethanol in order to minimize the primer
contamination.
Genome sequencing and assembly
For Sanger sequencing, puriﬁed viral genome was fragmented by
shotgun and fractions ranging from 1.4 to 2 Kbp were cloned into
pUC18 vector. Random sub-clones were sequenced using dye-
terminator chemistry on ABI 377 automated sequencers at the Well-
come Trust Sanger Institute (Hinxton, United Kingdom). The entire
sequence was read on both strands and the genome was assembled
with PHRAP/GAP4 (http://www.phrap.org/) (Bonﬁeld et al., 1995). For
454-Roche sequencing, 2 μg of the Phi29-ampliﬁed viral DNA was
used for the construction of a library using 454-Roche GS-FLX
Titanium system (454 Life Sciences, Roche). Sequencing reads obtained
with a FLX Genome Sequencer in the Parque Cientíﬁco de Madrid
were assembled in three steps with Newbler 2.5.3 (Roche). First, using
the GS Reference Mapper the reads were aligned to the ECTV-Naval
genome obtained by Sanger as reference under the parameters: 90%
minimum overlap and 95% identity. Second, a de novo assembly was
carried out with GS De Novo Assembler under more stringent para-
meters (90% bases overlap and 97% overlap identity) in order to
determine the inverted terminal repeat (ITR) regions. Finally, a second
mapping was carried out at 97% of identity in at least 90% of the
sequence length. For Illumina sequencing, 5 μg of the Phi29-ampliﬁed
viral DNA were used for the construction of a TruSeq library. Reads
obtained with a Genome Analyzer IIx in the Parque Cientíﬁco de
Madrid were mapped using the trial version of CLC-Genomics Work-
bench 5.5.1 (CLC bio) to the Sanger ECTV-Naval genome as reference
under the following parameters: 90% length overlap and 95%
similarity.
Analysis of fragment size by gel electrophoresis
A PCR ampliﬁcation of the region containing the central direct
repeat (DRIII) (Mendez-Rios et al., 2012) was carried out with the
primers forward (50-CCCGTTCCGTTGATAGAT-30) and reverse (50-
GGAAGAAGTACAATCTCTA-30). The PCR product was run in a 2%
agarose gel with a 100 bp ladder (Invitrogen) as marker. The most
intense band of each isolate was considered for the estimation of the
number of repeats. The sources of ECTV isolates used as templates
have been previously described (Smith and Alcami, 2000).
Genome analysis and annotation
The genomes were annotated using Artemis (Wellcome Trust
Sanger Institute) (Rutherford et al., 2000). Percentages of identity
and number of different nucleotides (nt) between the genomes
were obtained by full-length genome alignment using Geneious
Pro 6.1 (Biomatters). Open reading frames (ORFs) that code for
non-overlapping proteins with a minimum 120 nt, with similarity
to a poxvirus ortholog of known function or with preserved
domains were annotated as genes. Fragmented genes, generated
by deletion or insertion, with similarity to poxvirus functional
orthologs were annotated as pseudogenes. Genes and pseudo-
genes were named with a three letter acronym EVN or EVC (the
ﬁrst two letters standing for ECTV and the third letter indicating
the initial of the Naval or Cornell isolate) and numbered consecu-
tively from left to right region of the genome. Pseudogenes were
indicated with a P after the number. The schematic representation
of the ECTV-Naval genome was designed with the Artemis
DNAPlotter and reﬁned manually.
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Experimental infection of susceptible BALB/c and DBA/2 mice
Groups of ﬁve female BALB/c and DBA/2 mice, six to seven
weeks old, were purchased from Charles River Laboratories,
anesthetized using isoﬂurane and infected subcutaneously in the
left hind footpad with 1, 10 or 102 pfu of semi-puriﬁed ECTV-Naval,
ECTV-Cornell, ECTV-Moscow or PBS as control. Clinical signs of
illness and body weight loss were monitored daily for 19 days
post-infection (dpi). Mice were housed under biological safety
level 3 in a ventilated rack (Allentown) with free access to food
and water and 12 h light/12 h dark cycle. Animal experiments
were approved by the Ethical Committee of the Consejo Superior
de Investigaciones Cientíﬁcas and the Biological Safety Depart-
ment of the Centro de Biología Molecular Severo Ochoa, and
carried out according to European regulations.
Nucleotide sequence accession number
The genome sequence of ECTV-Naval was submitted to
GenBank with the accession number KJ563295.
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